MARKET

CTSO

CTSO

Cytosorbents
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.37
-0.22
-2.56%
After Hours: 8.33 -0.04 -0.48% 17:40 10/20 EDT
OPEN
8.48
PREV CLOSE
8.59
HIGH
8.71
LOW
8.28
VOLUME
234.35K
TURNOVER
--
52 WEEK HIGH
11.74
52 WEEK LOW
3.490
MARKET CAP
361.23M
P/E (TTM)
-16.2651
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
CytoSorbents and Aferetica Announce European Union Approval of the PerLife System and ECOS-300CY PerSorb Cartridge for Combined Perfusion and Purification of Solid Organs Dedicated to Transplant
CytoSorbents Corporation (NASDAQ: CTSO; USA) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce the European Union approval of Aferetica's PerLife™ ex vivo organ perfusion system and CytoSorbents' ECOS-300CY™ sorbent cartridge for the removal of inflammatory mediators during ex vivo organ perfusion. The integrated system was developed in concert to improve the preservation and quality of solid organs, like the kidneys and liver, following harvest and prior to transplant into a new recipient. Aferetica and CytoSorbents have worked closely together to ensure mutual compatibility of their technologies and will introduce the PerLife System and PerSorb™ (ECOS-300CY) adsorber dedicated to Aferetica, with a commercial launch in Italy this quarter.
PR Newswire · 6d ago
EU OKs use of a organ perfusion system with CytoSorbents' cartridge
CytoSorbents (CTSO) and Italy-based Aferetica have announced the European Union ((EU)) approval of a platform that comprises Aferetica's PerLife ex vivo organ perfusion system integrated with CytoSorbents' ECOS-300CY sorbent cartridge for the
Seekingalpha · 6d ago
CytoSorbents And Aferetica Announce European Union Approval Of The PerLife System And ECOS-300CY PerSorb Cartridge For Combined Perfusion And Purification Of Solid Organs Dedicated To Transplant
  NEW JERSEY and BOLOGNA, Italy, Oct. 14, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ:CTSO, USA)) and Aferetica srl (Italy), two pioneers in intensive care immunotherapy and blood purification, announce
Benzinga · 6d ago
CytoSorbents nabs DoD contract to support development of blood purifier
The U.S. Army Medical Research Acquisition Activity ((USAMRAA)) has awarded CytoSorbents (CTSO) a two-year contract valued at ~$1.1M to optimize development of its HemoDefend-BGA™ adsorber.The HemoDefend-BGA adsorber can rapidly remove >99%
Seekingalpha · 10/09 11:21
The U.S. Department of Defense awards $1.1M to CytoSorbents to optimize development of HemoDefend-BGA™
USAMRAA has awarded CytoSorbents (CTSO) a two-year SBIR Sequential Phase II contract valued at ~$1.1M to optimize development of the HemoDefend-BGA™ adsorber.The HemoDefend-BGA adsorber can rapidly remove >99% of anti-A and
Seekingalpha · 10/09 11:21
CytoSorbents' CytoSorb now available in Brazil
CytoSorbents (CTSO) has launched CytoSorb in Brazil to treat cytokine storm in cardiac surgery and critical illnesses such as COVID-19 infection.CytoSorb is a blood purification technology to treat cytokine storm and deadly inflammation
Seekingalpha · 09/21 11:34
CytoSorb Achieves Registration in Brazil and Is Now Commercially Available To Treat Cytokine Storm in COVID-19 Infection and Other Conditions
CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CytoSorb was granted medical device
PR Newswire · 09/21 11:08
Cytosorbents Corporation (NASDAQ:CTSO): Is Breakeven Near?
Cytosorbents Corporation (NASDAQ:CTSO) is possibly approaching a major achievement in its business, so we would like...
Simply Wall St. · 09/19 15:45
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CTSO. Analyze the recent business situations of Cytosorbents through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CTSO stock price target is 14.75 with a high estimate of 16.00 and a low estimate of 13.00.
EPS
Institutional Holdings
Institutions: 132
Institutional Holdings: 12.36M
% Owned: 28.64%
Shares Outstanding: 43.16M
TypeInstitutionsShares
Increased
36
1.46M
New
40
158.87K
Decreased
13
296.33K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Advanced Medical Equipment & Technology
+0.47%
Healthcare Equipment & Supplies
+0.08%
Key Executives
Chairman/Non-Executive Chairman/Director/Independent Director
Al Kraus
Chief Executive Officer/President/Director
Phillip Chan
Chief Financial Officer
Kathleen Bloch
Chief Operating Officer
Vincent Capponi
Director/Independent Director
Michael Bator
Independent Director
Edward Jones
Independent Director
Alan Sobel
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About CTSO
CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury and pancreatitis. In addition, CytoSorb is used in other inflammatory conditions, such as cardiac surgery, autoimmune disease flares, cancer, cytokine release syndrome in cancer immunotherapy and cancer cachexia.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Cytosorbents Corp stock information, including NASDAQ:CTSO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CTSO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CTSO stock methods without spending real money on the virtual paper trading platform.